Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Novartis will begin to progress the integration of MorphoSys, including full access to CPI-0610 (pelabresib), a novel BET inhibitor in combination with ruxolitinib for patients with myelofibrosis.
Lead Product(s): Pelabresib,Ruxolitinib Phosphate
Therapeutic Area: Oncology Product Name: CPI-0610
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition May 16, 2024
Details:
Through the acquisition, Novartis will strengthen its oncology pipeline with CPI-0610 (pelabresib), a novel and potentially practice changing treatment option with a well-tolerated safety profile provided in combination with ruxolitinib for patients with myelofibrosis (MF).
Lead Product(s): Pelabresib,Ruxolitinib Phosphate
Therapeutic Area: Oncology Product Name: CPI-0610
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation
Deal Size: $2,897.9 million Upfront Cash: $2,897.9 million
Deal Type: Acquisition February 05, 2024
Details:
Under the agreement, Incyte gains exclusive global rights for tafasitamab, a humanized Fc-modified CD19-targeting immunotherapy marketed in the U.S. as Monjuvi (tafasitamab-cxix) and outside of the U.S. as Minjuvi (tafasitamab).
Lead Product(s): Tafasitamab
Therapeutic Area: Oncology Product Name: Monjuvi
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Incyte Corporation
Deal Size: $25.0 million Upfront Cash: Undisclosed
Deal Type: Agreement February 05, 2024
Details:
CPI-0610 (pelabresib monohydrate) is an investigational BET inhibitor. It is being developed in combination with the JAK inhibitor ruxolitinib for the treatment of myelofibrosis.
Lead Product(s): Pelabresib,Ruxolitinib Phosphate
Therapeutic Area: Oncology Product Name: CPI-0610
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 20, 2023
Details:
CPI-0209 (tulmimetostat) is an investigational compound designed to exert anti-tumor activity by inhibiting the EZH2 and EZH1, which is investigated for the treatment of endometrial cancer.
Lead Product(s): Tulmimetostat,Carboplatin
Therapeutic Area: Oncology Product Name: CPI-0209
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 12, 2023
Details:
RO4909832 (gantenerumab) is fully-human mAB, studies did not meet their primary endpoint of slowing clinical decline. The level of beta-amyloid removal, the protein that builds up to make plaques in the brains of people with Alzheimer's disease.
Lead Product(s): Gantenerumab
Therapeutic Area: Neurology Product Name: RO4909832
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 14, 2022
Details:
GSK3196165 (otilimab) is an investigational human monoclonal antibody directed against GM-CSF (granulocyte-macrophage colony-stimulating factor) that is developed by GSK for the treatment of rheumatoid arthritis.
Lead Product(s): Otilimab,Methotrexate,Sulfasalazine
Therapeutic Area: Immunology Product Name: GSK3196165
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2022
Details:
CPI-0209 (tulmimetostat) is an oral, investigational next-generation selective dual inhibitor of EZH2 and EZH1 designed to improve on first generation EZH2 inhibitors via increased potency, longer residence time on target and a longer half-life.
Lead Product(s): Tulmimetostat
Therapeutic Area: Oncology Product Name: CPI-0209
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2022
Details:
The body of data presented at SOHO shows the long-term duration of response to Monjuvi (tafasitamab) in some patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem-cell transplant.
Lead Product(s): Tafasitamab,Lenalidomide
Therapeutic Area: Oncology Product Name: Monjuvi
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2022
Details:
Monjuvi (tafasitamab) incorporates an XmAb® engineered Fc domain, which mediates B-cell lysis through apoptosis and immune effector mechanism including Antibody-Dependent Cell-Mediated Cytotoxicity and Antibody-Dependent Cellular Phagocytosis.
Lead Product(s): Tafasitamab,Lenalidomide
Therapeutic Area: Oncology Product Name: Monjuvi
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: InnoCare Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 09, 2022